What this Trial Is About

Low grade glioma (LGG) is a slow-growing, highly invasive brain tumor that is difficult to visually distinguish from normal brain tissue, especially at the tumor borders. This challenge affects the ability to perform early maximal surgical removal, which is the standard treatment. Researchers are exploring the use of hyperspectral imaging (HSI) technology to improve real-time detection and differentiation of LGG tissue during surgery, aiming to support surgical decisions and enhance tumor removal. Patients undergoing standard surgical resection of LGG will have HSI data collected using a SnapScan HSI camera mounted on an operative microscope. Images will be taken before, during, and after tumor removal from specific points identified by a neuronavigational system on the exposed brain surface and cavity walls. Corresponding tissue biopsies will be taken from these points when tumor presence is expected, based on current intraoperative assessments. The study uses a "stop and go" design, starting with nine months of data collection and analysis to identify spectral patterns that distinguish tumor from normal brain tissue. If successful, the study will continue for an additional 26 months to expand data collection and develop software for rapid, real-time tissue detection. Participants will be involved during their surgical procedure, where HSI data and tissue samples are collected. Researchers will analyze hyperspectral image patterns comparing tumor tissue with normal brain tissue during surgery. The study focuses on creating a reliable dataset to explore the potential of this imaging technology. The study includes ongoing assessment of the imaging data and safety procedures, lasting up to 35 months if the study proceeds beyond the initial phase.

HyperSpectral Imaging in Low Grade Glioma